Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study by Modi, A et al.
ORIGINAL ARTICLE
Gastrointestinal symptoms and association with medication use
patterns, adherence, treatment satisfaction, quality of life, and
resource use in osteoporosis: baseline results of the MUSIC-OS
study
A.Modi1 & S. Sen1 & J. D. Adachi2 & S. Adami3 & B. Cortet4 & A. L. Cooper5 & P. Geusens6 &
D. Mellström7 & J. Weaver1 & J. P. van den Bergh6,8 & A. M. Nguyen1 & S. Sajjan1 &
MUSIC-OS Study Group
Received: 29 June 2015 /Accepted: 25 October 2015 /Published online: 4 December 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Summary The Medication Use Patterns, Treatment Satisfac-
tion, and Inadequate Control of Osteoporosis Study (MUSIC-
OS) is a prospective, observational study of women with
osteoporosis in Europe and Canada. At baseline, patients with
gastrointestinal symptoms reported lower adherence to osteo-
porosis treatment, treatment satisfaction, and health-related
quality of life, than those without gastrointestinal symptoms.
Introduction The aim of the study was to examine gastroin-
testinal (GI) symptoms and the association between GI symp-
toms and treatment adherence, treatment satisfaction, and
health-related quality of life (HRQoL) among osteoporotic
women in Europe and Canada.
Methods Baseline results are reported here for a prospective
study which enrolled postmenopausal, osteoporotic women
who were initiating (new users) or continuing (experienced
users) osteoporosis treatment at study entry (baseline). A
patient survey was administered at baseline and included the
occurrence of GI symptoms during 6-month pre-enrolment,
treatment adherence (adherence evaluation of osteoporosis
(ADEOS), score 0–22), treatment satisfaction (Osteoporosis
Treatment Satisfaction Questionnaire for Medications
(OPSAT-Q), score 0–100) and HRQoL (EuroQol-5 dimension
(EQ-5D) utility, score 0–1; OPAQ-SV, score 0–100). The
association between GI symptoms and ADEOS (experienced
users), OPSAT-Q (experienced users), and HRQoL (new and
experienced users) was assessed by general linear models
adjusted for patient characteristics.
Results A total of 2959 patients (2275 experienced and 684
new users) were included. Overall, 68.1 % of patients experi-
enced GI symptoms in the past 6 months. Compared with
patients without GI symptoms, patients with GI symptoms
had lower mean baseline scores on most measures. The mean
adjusted differences were ADEOS, −0.43; OPSAT-Q, −5.68;
EQ-5D, −0.04 (new users) and −0.06 (experienced users), all
P<0.01. GI symptoms were also associated with lower
OPAQ-SV domain scores: physical function, −4.17 (experi-
enced users); emotional status, −4.28 (new users) and −5.68
(experienced users); back pain, −5.82 (new users) and −11.33
(experienced users), all P<0.01.
Conclusions Patients with GI symptoms have lower treatment
adherence and treatment satisfaction and worse HRQoL than
patients without GI symptoms.
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Introduction
Osteoporosis-related fractures persist as a global health is-
sue despite the availability of effective treatments to reduce
fracture risk. In the European Union, osteoporosis affects
an estimated 22 million women and 5.5 million men,
resulting in 3.5 million new fragility fractures annually
and 37 billion euros per year in direct health care costs
[1]. In Canada, there were 57,413 acute care admissions,
832,594 hospitalized days, and $1.2 billion in acute care
costs attributable to osteoporosis fractures during 2007–
2008 [2]. Patients who sustain fragility fractures experience
significantly worse health-related quality of life (HRQoL)
[3–5] and face an increased risk of mortality [6, 7].
There are several treatment options with demonstrated
efficacy in reducing fracture risk in osteoporotic patients,
including bisphosphonates. Bisphosphonates are the most
commonly prescribed therapy. However, among patients
who initiate treatment, adherence to and persistence with
therapy is often poor in clinical practice. Among patients
initiating bisphosphonate therapy, only approximately
40–60 % are adherent to therapy during the first year
[8–10] and a similar proportion are non-persistent in their
first year of treatment [10–12]. The consequences of low
adherence and persistence include greater fracture risk
[10, 13] and the sequalae of higher health care utilization
and costs [14–16].
Gastrointestinal (GI) symptoms among patients on oral
bisphosphonates may also contribute to worse clinical out-
comes. Although controlled trials have found no differences
in the rate of GI symptoms among patients (with and without
pre-existing GI disorders) treated with oral bisphosphonates
compared with placebo [17, 18], analyses of real-world data
have noted upper GI complaints often manifesting as dyspep-
sia, gastroesophageal reflux, and nausea [19] and less
frequently as esophagitis [20] and gastric ulcers [21]. Patients
with a history of GI disorders are more likely to develop
symptoms on oral bisphosphonate treatment [22–24], and
both pre-treatment gastrointestinal complaints and complaints
while on treatment have been associated with discontinuation
of oral bisphosphonates and other osteoporosis therapies [22,
25–27]. Additionally, evidence from the POSSIBLE-US
observational study of osteopenic and osteoporotic women
suggests that patients who experience GI symptoms on treat-
ment have lower treatment satisfaction than patients without
GI complaints [26] and lower treatment satisfaction was asso-
ciated with a higher risk of treatment discontinuation or
switching [28]. GI complaints on treatment were also linked
to lower HRQoL among patients newly initiating therapy
[26]. However, the rate of GI symptoms and the relation-
ship between GI symptoms and patient-reported outcomes
has not been well explored in osteoporotic women in the
EU and Canada.
This study focuses on postmenopausal women in the EU
and Canada who were initiating or continuing oral phar-
macological therapy for osteoporosis at the start of the
study. The objectives were to identify treatment patterns,
GI symptoms, and the association between GI symptoms
and treatment adherence, treatment satisfaction, health-
related quality of life, and health care resource utilization.
Methods
Study design and participants
The study design, recruitment, and patient baseline char-
acteristics of the Medication Use Patterns, Treatment Sat-
isfaction, and Inadequate Control of Osteoporosis Study
(MUSIC-OS) have been previously reported [29]. In
brief, MUSIC-OS investigators enrolled postmenopausal
women aged 55 and older, with a physician diagnosis of
osteoporosis, from 96 primary care and specialty clinics
in Canada, France, Italy, the Netherlands, Sweden, and
the UK. The study was carried out in accordance with
the Declaration of Helsinki, the standards of good clinical
practice, and either the local ethics boards of the partici-
pating institutions or a central institutional review board.
All participants provided written informed consent prior
to study enrolment. Potential enrollees were identified at
each site at the time of a medical consultation. This anal-
ysis describes the results of data collected at the enroll-
ment (baseline) visit for new users who were initiating
oral pharmacological treatment for osteoporosis and
experienced users who were continuing the same oral
pharmacological treatment.
Qualifying oral pharmacologic treatment for osteoporo-
sis in MUSIC-OS included bisphosphonates (e.g.,
alendronate, risedronate, ibandronate), calcitonin, stron-
tium ranelate, and selective estrogen receptor modulators
(SERMs [e.g., raloxifene, and bazedoxifene]). Calcium,
vitamin D, and estrogen and other hormone replacement
therapy were not considered pharmacologic treatments for
osteoporosis in this study. New users were patients either
initiating qualifying oral pharmacological therapy at en-
rollment or receiving qualifying oral pharmacological
therapy for less than 3 months prior to enrollment with
no previous history of any osteoporosis pharmacological
therapy. Experienced users were receiving the same qual-
ifying oral pharmacological therapy for at least 3 months
continuously prior to enrollment and were continuing
treatment at the time of enrollment. Each cohort was fur-
ther categorized by the presence or absence of GI symp-
toms by asking patients at baseline if they had experienced
any GI symptoms in the 6 months prior to enrollment.
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Measures
Patients were interviewed, and their medical chart history was
reviewed during the enrolment visit (i.e., baseline visit) to
obtain information on qualifying oral pharmacological osteo-
porosis therapy (defined above), concomitant medications,
and GI symptoms. Concomitant medications included other
medications/supplements taken for osteoporosis (e.g., calcium
and/or vitamin D, estrogen and hormone replacement therapy,
parathyroid hormone), gastrointestinal conditions (e.g., ant-
acids), and drugs linked to gastrointestinal conditions, e.g.,
acetaminophen, non-steroidal anti-inflammatory drugs). The
presence and type of GI symptoms were assessed by asking
the patient if she had experienced any of a defined list of upper
(heartburn/acid reflux, upset stomach/indigestion, nausea/
vomiting, pain behind breastbone, pain or difficulty
swallowing, stomach pain above navel) or lower (diarrhea or
constipation, stomach pain below navel, bloating) GI prob-
lems in the last 6 months. Health care utilization in the
3 months prior to enrolment was assessed by asking patients
to report medical services utilized specific to osteoporosis-
related concerns and those specific to gastrointestinal-related
concerns. Service categories captured were visits to family
physician/general practitioner and specialists.
Patients completed four instruments to assess treatment ad-
herence, treatment satisfaction, and HRQoL. Adherence was
assessed among experienced users with the 12-item adherence
evaluation of osteoporosis (ADEOS) treatment questionnaire,
which has been validated in women with osteoporosis [30].
Scores range from 0 to 22 with scores ≥20 predicative of a
high probability of medication persistence. Treatment satisfac-
tion was measured with the Osteoporosis Treatment Satisfac-
tion Questionnaire for Medications (OPSAT-Q), which uses
Likert scales to assess four domains (treatment convenience,
confidence in daily functioning, overall satisfaction with treat-
ment, and side effects) with the total score reported on a 0–100
scale (higher scores indicating greater satisfaction) [31]. The
OPSAT-Q has been val ida ted in women tak ing
bisphosphonates [31]. HRQoL was evaluated with the
EuroQol-5 dimension (EQ-5D) utility which assesses health
state [32], and the disease-specific Osteoporosis Assessment
Questionnaire-Short Version (OPAQ-SV) which assesses
health status in three domains: physical function, emotional
status, and back pain [33].
Statistical analyses
The recruitment goal was 3300 treated patients to achieve a
sample size of 2640, assuming 20 % loss to follow-up. This
sample size is estimated assuming a normal distribution to
provide 95% confidence intervals at a 0.05 significance level.
We computed descriptive statistics for GI symptoms. The dif-
ference in the proportion of new and experienced users
reporting GI symptoms was examined by chi-squared test.
The association between the presence/absence of GI symp-
toms and ADEOS, OPSAT-Q, EQ-5D, and OPAQ-SV
scores was assessed with general linear models. Odd ratios
for GI- and OP-related health care utilization were comput-
ed by logistic regression models. Separate models were
constructed for each cohort (experienced vs. new user)
and each measure (ADEOS, OPSAT-Q, EQ-5D, OPAQ-
SV) and each component (general practitioner or specialist
visit) of GI- and OP-related health care utilization. Model-
ing was conducted in two phases: an initial full model
followed by a final reduced model. The initial full models
were adjusted for the following patient characteristics: age
group in years (50–59 [reference]; 60–69, 70–79; ≥80), race
(white [reference], non-white), BMI category (underweight
<18.5; normal 18.50–24.99 [reference]; overweight 25.00–
25.99; obese ≥30), duration of osteoporosis at study entry in
years (<1 [reference]; 1–<5, 5–10; >10), duration of pharma-
cological treatment for osteoporosis at study entry in years (<1
[reference]; 1–<5, 5–10; >10; this variable was excluded from
the model for new users), history of falls in the past 12 months
(yes, no [reference]), history of osteoporotic fracture at any
time in the past (yes, no [reference]), presence of any selected
comorbid conditions (yes, no [reference]; conditions included
hypertension, diabetes, chronic kidney disease, rheumatoid
arthritis, hypothyroidism, anorexia nervosa, celiac disease, in-
flammatory bowel disease, lactose intolerance, lupus, asthma,
stroke, dementia, chronic obstructive pulmonary disease),
combination treatment (receiving bisphosphonates and non-
bisphosphonates, receiving bisphosphonates [reference]),
treatment class (receiving non-bisphosphonates, receiving
bisphosphonates [reference]), and concomitant medication
use (yes, no [reference]). Because not all participants had
values for each covariate (e.g., race information was missing
in France), the final model was a reduced model selected by
using the subset of covariates in the full model that was sig-
nificant at P≤0.15 by backward elimination. The ADEOS
and OPSAT-Q scores were not modeled for new users be-
cause these patients were either initiating osteoporosis
therapy at study entry or had <3 months exposure to ther-
apy. Covariates with unstable confidence intervals were
excluded from models.
Results
Enrollment
We enrolled 3335 patients from 96 sites. The number of pa-
tients (% of total study enrollment) and number of sites by
country, respectively were UK, 873 patients (26.2%), 22 sites;
Canada, 760 patients (22.8 %), 15 sites; France, 661 patients
(19.8 %), 27 sites; Italy, 593 patients (17.8 %), 22 sites;
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Netherlands, 225 patients (6.7 %), 7 sites; Sweden, 223
(6.7 %), 3 sites. Of the 3335 enrolled patients, 2980 were
protocol eligible, treated patients. After excluding 21
patients with missing data for GI symptoms, there were
2275 patients in the experienced user cohort and 684 pa-
tients in the new user cohort.
Treatment patterns
Bisphosphonates were the most common treatment overall
(79.9 %) and among each user cohort and GI symptom group
(Table 1). Among new users, 44.8 % were not receiving phar-
macological osteoporosis therapy at the baseline visit.
Although inclusion in this analysis required that all patients
be treated with qualifying osteoporosis medications, the per-
centage of new users on pharmacological therapy at enroll-
ment is less than 100 because some new users were prescribed
their treatment on the day of the enrollment visit. Overall,
10.2 % of patients were taking only non-pharmacological oral
medications (calcium and/or vitamin D treatment, estrogen,
and/or hormone replacement therapy), and the majority of
these patients were new users. Among all patients, 71.8 %
reported taking a calcium and/or vitamin D supplement (data
not shown). Experienced users had been taking oral pharma-
cologic therapy for approximately 4 years.
Frequency of gastrointestinal symptoms
There were 2015 (68.1 %) patients who reported GI symp-
toms in the 6 months prior to enrollment (Table 2). The pro-
portion of experienced users reporting GI symptoms was
higher than new users (69.1 vs. 64.6 %; P<0.03). The most
common upper GI symptoms reported by all patients were
heartburn/acid reflux (35.0 %) followed by upset stomach/
indigestion (28.4 %). Diarrhea or constipation (38.2 %)
and bloating (37.3 %) were the most frequently reported
lower GI symptoms.
Adherence and treatment satisfaction
Among experienced users (n=2228), 49.2 % had an ADEOS
score ≥20, indicative of a high probability of medication
Table 1 Osteoporosis treatment patterns at enrolment
New users Experienced users All users
Characteristic GI
Symptoms
(n=442)
No GI
Symptoms
(n=242)
All
(n=684)
GI
Symptoms
(n=1,573)
No GI
Symptoms
(n=702)
All
(n=2,275)
GI
Symptoms
(n=2015)
No GI
Symptoms
(n=944)
All
(n=2,959)
Osteoporosis medication
Bisphosphonates, n (%) 223
(50.5)
131
(54.1)
354
(51.8)
1372
(87.2)
606
(86.3)
1978
(86.9)
1595
(79.2)
737 (78.1) 2378
(79.9)
Non-bisphosphonates, n (%) 23 (5.2) 7 (2.9) 30 (4.4) 209 (13.3) 108 (15.4) 317
(13.9)
232 (11.5) 115 (12.2) 347
(11.7)
Bisphosphonates and non-
bisphosphonates, n (%)
2 (0.5) 0 (0.0) 2 (0.3) 9 (0.6) 12 (1.7) 21 (0.9) 11 (0.5) 12 (1.3) 23 (0.8)
Not receiving qualifying oral
pharmacological osteoporosis
medicationa, n (%)
198 (44.8) 104 (43.0) 302 (44.2) 1 (0.1) 0 (0.0) 1 (0.0)b 199 (9.9) 104 (11.0) 303 (10.2)
Duration of qualifying oral,
pharmacological osteoporosis
medication at enrolment, months
Any therapy, mean (SD) 0.3 (0.61) 0.2 (0.57) 0.3
(0.60)
48.8
(39.11)
46.1
(36.92)
48.0
(38.46)
42.3
(39.98)
38.6
(37.79)
41.1
(39.33)
Bisphosphonates, mean (SD) 0.3 (0.60) 0.2 (0.56) 0.2
(0.58)
48.0
(38.19)
43.8
(35.51)
46.7
(37.43)
41.3
(39.10)
36.1
(36.27)
39.7
(38.30)
Non-bisphosphonates, mean (SD) 0.4
(0.72)
0.4
(0.79)
0.4
(0.72)
51.5
(43.71)
55.0
(44.91)
52.7
(44.09)
46.5
(44.22)
51.7
(45.44)
48.2
(44.63)
a Some new users had not started qualifying oral pharmacological osteoporosis medication (bisphosphonates [e.g., alendronate, risedronate,
ibandronate)], calcitonin, strontium, and SERM [raloxifene], and bazedoxifene) at the enrolment visit because they received their prescription on the
day of the enrolment visit. Calcium and/or vitamin D treatment and estrogen and/or hormone replacement therapy were not considered relevant
osteoporosis treatment
b One patient classified as an experienced user was reported as not having received qualifying oral pharmacological osteoporosis medication. This patient
was removed from the analysis of the association between gastrointestinal symptoms and patient-reported outcomes
GI gastrointestinal
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persistence (data not shown). ADEOS scores ≥20 were less
frequent among experienced users with GI symptoms com-
pared with users without GI symptoms (45.5 vs. 57.6 %;
data not shown). The association between GI symptoms
and ADEOS and OPSAT-Q scores, adjusted for patient
demographic and clinical characteristics, is shown in
Table 3. The adjusted mean difference between the GI
and no GI symptom groups was −0.43 (P<0.001) with
lower mean ADEOS scores in the GI symptom group.
Treatment satisfaction measured by OPSAT-Q score was
also significantly lower among experienced users with GI
symptoms: The mean adjusted difference between the GI
and no GI symptom groups was −5.68 (P<0.0001).
Health-related quality of life
The association between GI symptoms and measures of
HRQoL, adjusted for patient characteristics, is shown in
Table 4. Compared with patients without GI symptoms,
patients with GI symptoms had significantly lower mean
adjusted EQ-5D utility scores in both the new user (mean
difference −0.04, P<0.0099) and experienced user (mean
difference −0.06, P<0.0001) cohorts. For the disease-
specific OPAQ-SV, GI symptoms in new users were asso-
ciated with significantly lower adjusted mean scores in the
domains of emotional status (mean difference −4.28,
P < 0.01) and back pain (mean difference −5.82,
P<0.01). Experienced users with GI symptoms had lower
scores in all three domains with adjusted mean differences
of −4.17 for physical function, −5.68 for emotional status,
and −11.33 for back pain (all P<0.0001).
Health care resource utilization
The likelihood of osteoporosis-related and GI-related
health care utilization among patients with GI symptoms
Table 2 Patient-reported gastrointestinal symptoms during 6 months prior to enrollment
New users Experienced users All users
GI symptoms
(n=442)
All
(n=684)
GI symptoms
(n=1573)
All symptoms
(n=2275)
GI symptoms
(n=2015)
All
(n=2959)
n (%) % n (%) % n (%) %
Any GI problems in the past
6 months
442 (100) 64.6 1573 (100) 69.1 2015 (100) 68.1
Any upper GI 341 (77.1) 49.9 1232 (78.3) 54.2 1573 (78.1) 53.2
Heartburn/acid reflux 210 (47.5) 30.7 826 (52.5) 36.3 1036 (51.4) 35.0
Upset stomach/indigestion 179 (40.5) 26.2 661 (42.0) 29.1 840 (41.7) 28.4
Nausea/vomiting 76 (17.2) 11.1 318 (20.2) 14.0 394 (19.6) 13.3
Pain behind breastbone 111 (25.1) 16.2 339 (21.6) 14.9 450 (22.3) 15.2
Pain or difficulty swallowing 45 (10.2) 6.6 233 (14.8) 10.2 278 (13.8) 9.4
Stomach pain above navel 94 (21.3) 13.7 318 (20.2) 14.0 412 (20.4) 13.9
Any lower GI 344 (77.8) 50.3 1261 (80.2) 55.4 1605 (79.7) 54.2
Diarrhea or constipation 226 (51.1) 33.0 904 (57.5) 39.7 1130 (56.1) 38.2
Stomach pain below navel 87 (19.7) 12.7 349 (22.2) 15.3 436 (21.6) 14.7
Bloating 238 (53.8) 34.8 867 (55.1) 38.1 1105 (4.8) 37.3
GI gastrointestinal
Table 3 Multivariate analyses of the association between GI symptoms and treatment adherence (ADEOS) and treatment satisfaction (OPSAT-Q)
scores for experienced users
n GI symptomsa No GI symptomsa Differencea (95 % CI) P value
ADEOS score (experienced users)b 2225 19.02 19.45 −0.43 (−0.672, −0.182) 0.0007
OPSAT-Q score (experienced users)c 2212 77.94 83.62 −5.68 (−7.017, −4.335) <0.0001
aValues are adjusted means from the generalized linear model with backward elimination
b Scored 0–22 with higher scores indicating greater adherence to treatment. Adjustment variables retained in the model were body mass index, duration
of osteoporosis, and treatment class
c Scored 0–100 with higher scores indicating greater treatment satisfaction. Adjustment variables retained in the model were age, body mass index,
history of falls, treatment class, and concomitant medication use
GI gastrointestinal
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(reference: no GI symptoms), adjusted for patient charac-
teristics, is shown in Fig. 1. Among new users with GI
symptoms, there was a non-significant trend for higher
odds of visiting general practitioners and specialists for
osteoporosis-related services compared with new users
without GI symptoms. However, experienced users with
GI symptoms had a signif icant ly higher r isk of
osteoporosis-related service utilization for general practi-
tioner visits (odds ratio [OR]: 1.35, 95 % CI=1.05–1.73,
P<0.03) but not specialist visits. The most pronounced
difference between experienced users with and without
GI symptoms was in GI-related service utilization. Experi-
enced users with GI symptoms had approximately ninefold
higher risk (95 % CI=4.58–17.86, P<0.0001) for GI-
related general practitioner visits and 4.2 higher odds
(95 % CI=1.79–9.93, P=0.001) of GI-related specialist
visits compared with experienced users with no GI
symptoms.
Discussion
The results of this baseline analysis of treated patients in
MUSIC-OS reveal the high rate of GI symptoms in this cohort
and the negative association of GI symptoms with patient-
reported outcomes. The presence of GI symptoms was asso-
ciated with small but consistently negative decrements in
medication adherence, treatment satisfaction, and HRQoL.
At baseline, 68.1 % of patients reported GI symptoms in
the last 6 months which is higher than observed in either
POSSIBLE-EU [34] or POSSIBLE-US [26]. This is likely a
result of methodological differences in capturing GI disorders.
In the POSSIBLE-EU study, 22 % of patients had current or
prior upper GI disorders and 9 % had current or prior lower GI
disorders [34]. However, POSSIBLE-EU employed a
narrower list of specific upper (GERD reflux, dyspepsia)
and lower GI (irritable bowel syndrome, Crohn’s disease) dis-
orders than MUSIC-OS, and site investigators (not patients)
Table 4 Association between GI
symptoms and measures of
health-related quality of life for
new and experienced users
n GI symptomsa No GI symptomsa Differencea (95 % CI) P value
EQ-5D utility scoreb
New users 678 0.74 0.78 −0.04 (−0.064, −0.009) 0.0099
Experienced users 2258 0.75 0.81 −0.06 (−0.071, −0.041) <0.0001
OPAQ-SV physical function scorec
New users 675 69.23 70.42 −1.18 (−4.105, 1.743) 0.4279
Experienced users 2267 71.93 76.10 −4.17 (−5.812, −2.536) <0.0001
OPAQ-SV emotional status scored
New users 675 58.62 62.90 −4.28 (−7.292, −1.278) 0.0053
Experienced users 1788 57.46 63.14 −5.68 (−7.560, −3.798) <0.0001
OPAQ-SV back pain scoree
New users 674 52.19 58.01 −5.82 (−10.200, −1.439) 0.0093
Experienced users 2269 53.54 64.87 −11.33 (−13.717, −8.945) <0.0001
aValues are adjusted means from the generalized linear model with backward elimination
b Scored 0–1; 0=worst imaginable health, 1=best imaginable health. Adjustment variables retained in the model
for new users were age, body mass index, duration of osteoporosis, history of fractures, history of falls, and
concomitant medication use. Adjustment variables retained in the model for experienced users were age, body
mass index, duration of osteoporosis, history of fractures, history of falls, comorbidities, treatment class, and
concomitant medication use
c Scored 0–100 with higher scores indicating better health status. Adjustment variables retained in the model for
new users were age, body mass index, history of fractures, history of falls, treatment class, and concomitant
medication use. Adjustment variables retained in the model for experienced users were age, body mass index,
duration of osteoporosis, duration of osteoporosis treatment, history of fractures, history of falls, treatment class
and concomitant medication use
d Scored 0–100 with higher scores indicating better health status. Adjustment variables retained in the model for
new users were age, body mass index, history of fractures, and treatment class. Adjustment variables retained in
the model for experienced users were age, race, body mass index, duration of osteoporosis, duration of osteo-
porosis treatment, history of fractures, history of falls, treatment class, comorbidities, and concomitantmedication
use
e Scored 0–100 with higher scores indicating better health status. Adjustment variables retained in the model for
new users were bodymass index, treatment class, and concomitant medication use. Adjustment variables retained
in the model for experienced users were age, body mass index, duration of osteoporosis treatment, history of
fractures, history of falls, treatment class, and concomitant medication use
GI gastrointestinal
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reported GI disorders which may have limited reporting to
those GI disorders that resulted in medical consultation or
treatment. In the POSSIBLE-US study, 21 % of patients
reported a constellation of upper and lower GI symptom sim-
ilar to those defined in the MUSIC-OS protocol [26]. Howev-
er, our results are based on a 6-month recall period, and
POSSIBLE-US symptoms were captured “at study entry.”
The recall period is a likely contributor to the difference in
rate of GI symptoms between the two studies. For example,
31 % of POSSIBLE-US participants had a history of gastro-
esophageal reflux disease, a subset of upper GI symptoms,
which is higher than the rate (21 %) reported for all upper
and lower GI symptoms at study entry. The proportion of
patients using GI medications was similar among the two stud-
ies: 20.7 % of MUSIC-OS patients used GI medications in the
last 12 months compared with approximately 25 % of
POSSIBLE-US participants at study entry, suggesting a similar
rate of GI conditions treated with medications although the
difference in recall period (last 12 months vs. study entry)
precludes a direct comparison. Irrespective of methodological
differences, the results of POSSIBLE-US andMUSIC-OS sug-
gest that GI complaints are quite common among women ini-
tiating or continuing osteoporosis therapy.
Among all experienced users (with and without GI
symptoms), only 49.2 % had an ADEOS score ≥20, which
is indicative of a high probability of medication persistence.
Although ADEOS scores were not well correlated with adher-
ence as measured bymedication possession ratio (MPR) in the
validation study [30], our results are within the range of
adherence to osteoporosis therapy observed in administrative
claims studies that calculated adherence as MPR. An MPR
threshold of 0.80 is commonly used to distinguish between
adherence and non-adherence; in the first year of therapy,
typically 34–55 % of patients are adherent to pharmacological
osteoporosis treatments [8–10]. GI symptoms were associated
with a small but significant decrease in ADEOS scores. The
association between GI symptoms and lower ADEOS scores
is consistent with previous studies of osteoporosis medication
persistence during follow-up. In POSSIBLE-US, women with
GI symptoms at study entry were 38 % more likely to discon-
tinue therapy within 6 months [26]. A higher risk of osteopo-
rosis therapy discontinuation has been observed among pa-
tients taking GI medication [35, 36]. MUSIC-OS patients
are being followed for 12 months, and future analysis will
explore the relationship between recurrent GI symptoms, ther-
apy discontinuation, and adherence as measured by ADEOS
scores.
GI symptoms were also associated with consistently lower
treatment satisfaction and HRQoL scores. In US studies, dec-
rements in treatment satisfaction have been linked with
increasing severity of side effects [28] and with the presence
of GI side effects in particular [26]. Women treated with
bisphosphonates were more likely to report GI side effects
than women treated with other osteoporosis therapies [26],
and upper GI symptoms during bisphosphonate therapy are
a prominent risk factor for early treatment discontinuation
[27]. The lower HRQoL scores we observed in patients with
GI symptoms are also consistent with POSSIBLE-US results:
Among new users, GI side effects at 6 months were associated
with lower mean OPAQ-SVemotional status at 6 months [26]
and lower OPAQ-SV physical function at study entry predicted
non-persistence with initial therapy [37]. Our results coupled
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
2.0
a b
0
O
dd
s R
a
o 
an
d 
95
%
 C
on
ﬁd
en
ce
 In
te
rv
al
GP Visi
1.89
0.87
1.28
t (n=681)
New U
Specialist Visi
sers
Osteopo
1.87
0.92
1.31
t (n=681) G
rosis-related 
1.05
1.73
1.3
P Visit (n=2,2
Exp
Resource Use
5
67) Special
erienced Use
*P<0.05
1.19
0.68
0.90
ist Visit (n=1,7
rs
69)
17.86
9.93
4.58
1.79
9.04
4.21
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
)762,2=n(tisiVtsilaicepS)762,2=n(tisiVPG
O
dd
s R
a
o 
an
d 
95
%
 C
on
ﬁd
en
ce
 In
te
rv
al
Experienced Users
GI-related Resource Use 
*P<0.0001
*P=0.001
Fig. 1 a Likelihood of osteoporosis-related health care resource use for
new and experienced users with and without GI symptoms. Values are
adjusted odds ratios from the logistic regression model with backward
elimination. Adjustment variables retained in the model for GP visits
were as follows: among new users: treatment class and concomitant
medication use; among experienced users: duration of osteoporosis,
history of fractures, comorbidities, and treatment class. Adjustment
variables retained in the model for specialist visits were as follows:
among new users: treatment class, concomitant medication use, and
comorbidities; among experienced users: age, race, duration of
osteoporosis, history of fractures, and treatment class: GI
gastrointestinal, GP general practit ioner. b Likelihood of
gastrointestinal-related health care resource use for experienced users
with and without GI symptoms. Values are adjusted odds ratios from
the logistic regression model with backward elimination. Adjustment
variables retained in the model for GP visits were as follows: age
group, duration of osteoporosis, history of fractures, history of falls,
treatment class, and concomitant medication use. Adjustment variables
retained in the model for specialist visits were body mass index, duration
of osteoporosis treatment, history of fractures, and concomitant
medication use. GI gastrointestinal, GP general practitioner
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with previous studies suggest that the selection of pharmacolog-
ic treatment for osteoporotic women should account for pre-
existing GI symptoms and the potential for posttreatment GI
symptoms to minimize the risk of therapy discontinuation.
MUSIC-OS is an observational study, and there are inherent
limitations. In order to ensure robust implementation of the pro-
tocol, we screened sites based on their experience and ability to
conduct observational research which may have biased the sam-
ple to physicians who are more engaged in the clinical manage-
ment of osteoporosis. Self-selection bias may have occurred for
both physicians who chose to participate and patients who
elected to enroll. GI symptoms in the 6 months prior to baseline
were patient-reported and may be subject to recall bias. Further,
the presence of GI symptoms did not require evidence ofmedical
consultation or treatment; thus, the severity of symptoms cannot
be ascertained. Although GI symptoms were associated with
lower scores on patient-reported outcomes, we cannot infer cau-
sation. Further, although scores in patients with GI symptoms
were consistently and significantly lower than patients without
GI symptoms, the differences were small and may not be clini-
cally significant. We adjusted scores for multiple patient demo-
graphic and clinical characteristics; however, there may have
been other unmeasured factors that could have influenced results.
Conclusions
Our results suggest that GI symptoms may deter patients from
complying with therapy and have an adverse effect on treat-
ment satisfaction, quality of life, and use of health care re-
sources. MUSIC-OS will follow treated patients for 1 year
and provide a comprehensive assessment of contemporary
treatment patterns and patient-reported outcomes in Europe
and Canada. Future analyses will explore overall medication
discontinuation/switching patterns, patient rationale for discon-
tinuation, adherence, treatment satisfaction, HRQoL, fracture
incidence, and health care utilization. The association between
treatment-emergent GI symptoms and these outcomes will also
be assessed. These results will provide additional insight to
improve clinical management of osteoporotic women.
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Appendix
Table 5
Investigator Name Site Name Department City State / Province Country
Dr. Jonathan Adachi Hamilton Ontario Canada
Dr. Aliya Khan Oakville Bone Centre Oakville Ontario Canada
Dr. Bradley Schweitzer The Medical Arts Health
Research Group
Powell River BC Canada
Dr. Kevin Saunders Rivergrove Medical Clinic Winnipeg Manitoba Canada
Dr. Miranda Du Preez The Medical Arts Health
Research Group
Kamloops BC Canada
Dr. Kenneth Bayly Saskatoon Saskatchewan Canada
Dr. Tersia Lichtenstein The Medical Arts Health
Research Group
Kelowna BC Canada
Dr. Richard Boroditsky Victoria General Hospital Mature Women's Centre Winnipeg Manitoba Canada
Dr. John S. Corey The Medical Arts Health
Research Group
West Vancouver BC Canada
Dr. Jay Sinha Steeple Hill Medical Centre Pickering Ontario Canada
Dr. Jack Kooy The Medical Arts Health
Research Group
Penticton BC Canada
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Table 5 (continued)
Investigator Name Site Name Department City State / Province Country
Dr. Arun Nayar Saskatoon Saskatchewan Canada
Dr. Suzanne Arndt Regina Medical Centre Regina Saskatchewan Canada
Dr. Iman Mohamed The Bone Wellness Centre Toronto Ontario Canada
Dr. Wojciech P. Olszynski Osteoporosis Centre Saskatoon Saskatchewan Canada
Isabelle Legroux Centre Hospitalier Régional
Universitaire de Lille
Service de Rhumatologie Lille France
Sandrine Malochet
Guinamand
Hôpital Gabriel Montpied Service de Rhumatologie Clermont-Ferrand France
Marie Christine De
Vernejoul
Hopital lariboisière Paris France
Christian Roux Hôpital Cochin Paris France
Eric Thomas Lapeyronie hospital Rheumatology Montpellier France
Florence Lévy-Weil Centre Hospitalier Argenteuil France
Corina Ursu Amiens Hospital
Association Predos
Service de Rhumatologie Chu Nord France
Bernard Cortet Centre Hospitalier Régional
Universitaire de Lille
Service de Rhumatologie Lille Cedex France
Francois Barucq Orthez France
Olivier Bisch Bischheim France
Philippe Bouche Bully-Les-Mines France
Nicolas Breton Beziers France
François Lacoin Cabinet Médical du Centre Albens France
Georgios Makridis Obernai France
Philippe Marmor Strasbourg France
Marcel Ruetsch Dessenheim France
Denis Taminau Rosiers
D'egletons
France
Michel Bismuth Labarthe-Sure-
Leze
France
Michel Bourgoin Gemenos France
Didier Sacareau Labarthe-Sure-
Leze
France
Christian Scellier Vourey France
Jean-Louis Wurtz Mundolsheim France
Dr. Stephane Le Mouel HINX France
Dr. Claude Bortolotti Oignies France
Dr. Bernard Lauer Colombey-les-
belles
France
Dr. Hervé Amar MARSEILLE France
Dr. Didier Cadinot BROGLIE France
Dan Mellström University of Gothenburg Public Health and Community
Medicine
Goteborg Sweden
Karl-Goran Thorngren Skane University Hospital Department of Orthopaedics Lund Sweden
Kristina Akesson Skåne University Hospital Clinical and Molecular
Osteoporosis Unit
Malmo Sweden
Giorgio Gandolini Castellanza Varese Italy
Mario Barbagallo Cattedra Di Geriatria Via
Del Vespro
Palermo Italy
Ranuccio Nuti University of Siena Internal Medicine Siena Italy
Marco Di Monaco Centro Specializzato Malattie Metaboliche
dell'Osso
Torino Italy
Gloria Bonaccorsi University of Ferrara Menopause and Osteoporosis
Center
Ferrara Italy
Sandro Giannini Padova Italy
Silvano Adami Azienda Ospedaliera -
Università di Verona
Riabilitazione Reumatologica Verona Italy
Antonio Del Puente Napoli Italy
Salvatore Minisola Rome Italy
Umberto Tarantino Rome Italy
Maria Luisa Brandi Internal Medicine Florence Italy
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Table 5 (continued)
Investigator Name Site Name Department City State / Province Country
Ombretta Di Munno U.O. Reumatologia Pisa Italy
Giovanni Mario D'Avola Catania Sicily Italy
Maurizio Caminiti Reggio Calabria Italy
Bruno Frediani Siena Italy
Claudio Marcocci University of Pisa Department of Endocrinology Pisa Italy
Franco Grimaldi Endocrinology and
Metabolism Unit
Udine Italy
Paolo Falaschi Azienda Ospedaliera Sant'Andrea UOS di Geriatria Rome Italy
Mario Biondi Centri osteoporosi e malattie del
metabolismo osse
Forli Italy
Giulia Letizia Mauro Palermo Italy
Francesco Paolo Cantatore Clinica Reumatologica Università
di Foggia
Ospedale Colonnello D'Avanzo Foggia Italy
Maurizio Muratore Ospedale Galateo ASL Lecce Reumatologia Lecce Italy
Dr. den Heijer VU University Medical Center Department of Internal Medicine/
Endocrinology
Amsterdam The Netherlands
Neveen A.T. Hamdy Leiden University Medical Center Department of Endocrinology &
Metabolic Diseases
Leiden The Netherlands
H.R. Franke Medisch Spectrum Twente VKC 17 Gynaecologie/research Enschede The Netherlands
JPW van den Bergh VieCuri Medical Center Dept. Internal Medicine Venlo The Netherlands
Ton Boermans Losser The Netherlands
Adriaan Kooy Bethesda Diabetes Research
Center
Hoogeveen Drenthe The Netherlands
Nicolaas K. Valk Beverwijk Noord Holland The Netherlands
Patrick Eavis Oldfield Surgery Bath UK
Robert Brownlie Valleyfield Health Centre High Valleyfield Fife UK
Jon Brunskill The Pulteney Practice Bath Somerset UK
Michael Gumbley Westbury Group Practice White Horse Health Centre Westbury Wiltshire UK
Richard Gaunt Rowden Surgery Chippenham Wiltshire UK
Jennifer Litchfield Pound Hill Medical Group Crawley West Sussex UK
G D Martin Greenwood and Sneinton Family
Medical Centre
Sneinton Nottingham UK
Boo McConnell St. James' Surgery Bath UK
Terry McCormack Whitby Group Practice, Spring
Vale Medical Centre
Whitby North Yorkshire UK
Narayanan Annamalai Albany House Medical Centre Wellingborough Northants UK
Devi Srinivasan Leicester Terrace Health Care Centre Northampton Northamptonshire UK
Alun Cooper Bridge Medical Centre Crawley West Sussex UK
Amrit Takhar Wansford and Kings Cliffe practice Cambridgeshire Cambridgeshire UK
Trevor Gooding Atherstone Surgery Warwickshire UK
Paul Conn Belfast UK
Ian Parker Beehive Surgery Bath Somerset UK
Michael Redmond Broughshane Medical Practice Broughshane UK
John Calvert Waterloo Medical Centre Blackpool Lancashire UK
Dr. Cookson Bradford Road Medical Centre Trowbridge Wiltshire UK
Paul Ainsworth Sherbourne Medical Centre Leamington Spa Warwickshire UK
Amardeep Heer Danetre Medical Practice Daventry Northamptonshire UK
Nell Wyatt The Health Centre Station Approach Wiltshire UK
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